Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients
| Tracking Information | |
|---|---|
| First Received Date ICMJE | March 6, 2012 |
| Last Updated Date | January 23, 2013 |
| Start Date ICMJE | May 2012 |
| Primary Completion Date | January 2013 (final data collection date for primary outcome measure) |
| Current Primary Outcome Measures ICMJE |
Chest tube losses [ Time Frame: Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs) ] [ Designated as safety issue: No ] Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. |
| Original Primary Outcome Measures ICMJE | Same as current |
| Change History | Complete list of historical versions of study NCT01574105 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE |
Transfusion Events [ Time Frame: Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs) ] [ Designated as safety issue: No ] Transfusion events to recorded will be units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate. |
| Original Secondary Outcome Measures ICMJE | Same as current |
| Current Other Outcome Measures ICMJE | Not Provided |
| Original Other Outcome Measures ICMJE | Not Provided |
| Descriptive Information | |
| Brief Title ICMJE | Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients |
| Official Title ICMJE | Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients |
| Brief Summary | Blood is anticoagulated using a drug named heparin during open-heart surgery to allow it to safely pass through the heart-lung machine which pumps the blood throughout the body during the surgery. Each patient is given the heparin they need for their surgery. This means some patients receive more or less heparin than other patients. In this study, the investigators will be evaluating the current anticoagulation protocol for open heart surgery in use at the Royal University Hospital. The goal of this project is to compare patients who require and receive more heparin for proper anticoagulation to those patients who require and receive less heparin. Open-heart surgery will proceed according to the standard hospital protocol. All research participants will be treated according to standard post-open heart surgery protocol in the ICU. This will include measurement of blood loss by keeping track of chest tube outputs and administration of blood transfusions. This study focuses on Saskatoon Health Region patients having open heart surgery in terms of the protocol for anticoagulation and blood transfusions. |
| Detailed Description | This study examines heparin doses of patients having cardiopulmonary bypass supported surgery in terms of their sensitivity and resistance to heparin which is the standard anticoagulant used. The investigators use the Heparin Management System, an analyser that performs a heparin dose response test. In this test, a patient's whole blood is mixed with increasing amounts of heparin to determine the required dose to achieve a set level of anticoagulation. Patients who are found to resistant to heparin and needing a higher dose are thought by some to bleed more post operatively. It is my view that when the patient is given the correct amount of heparin which is then reversed by the correct amount of protamine (the reversal agent) the bleeding is not determined by heparin dose. Hypothesis statement: Higher doses of heparin do not cause increased postoperative bleeding and transfusion events in the postoperative CPB patient. Purposes of the Study
This is a prospective observational study. Patients will be divided into two groups dependant upon the results of their heparin dose response test; sensitive or resistant. Two groups of thirty will be selected to achieve 90% power at the 0.025 level of significance using a one-sided two-sample t-test. The primary investigator will collect all data and submit the means to the statistician. Based on anecdotal experience the investigators expect there will be no difference between the two groups in terms of chest tube losses and transfusion events post-operatively. This work is quite relevant to the investigators daily practice. Every open heart patient is anticoagulated with heparin and bleeds post operatively. The investigators goal is a reproducibly safe anticoagulation level and an acceptable level of chest tube losses. This translates to getting patients out of the operating room in a timely fashion and minimizing transfusion events. |
| Study Type ICMJE | Observational |
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
| Target Follow-Up Duration | Not Provided |
| Biospecimen | Not Provided |
| Sampling Method | Non-Probability Sample |
| Study Population | On the date of surgery, the patient would be brought to the operating room. The first blood sample would be drawn prior to heparinization. This would include analysis for Activated Clotting Time, Heparin Concentration/Heparin Dose Response, antithrombin and Thrombelastograph. During this first sampling interval, the patient's Heparin Sensitivity or Resistance is determined by Heparin Dose Response (slope). The following values would determine which one of the two study groups the patient would be assigned:
|
| Condition ICMJE | Coronary Artery Disease |
| Intervention ICMJE | Not Provided |
| Study Group/Cohort (s) |
|
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Completed |
| Enrollment ICMJE | 66 |
| Completion Date | January 2013 |
| Primary Completion Date | January 2013 (final data collection date for primary outcome measure) |
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
Intraoperative:
|
| Gender | Both |
| Ages | 40 Years to 85 Years |
| Accepts Healthy Volunteers | Yes |
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
| Location Countries ICMJE | Canada |
| Administrative Information | |
| NCT Number ICMJE | NCT01574105 |
| Other Study ID Numbers ICMJE | 12-37 |
| Has Data Monitoring Committee | No |
| Responsible Party | Mark Rosin, University of Saskatchewan |
| Study Sponsor ICMJE | University of Saskatchewan |
| Collaborators ICMJE | Not Provided |
| Investigators ICMJE | Not Provided |
| Information Provided By | University of Saskatchewan |
| Verification Date | January 2013 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|